UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 296

of 'Overview of neurologic complications of non-platinum cancer chemotherapy'

296
TI
Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
AU
Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A
SO
Tumori. 2012;98(5):139e.
 
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
AD
Drug Development Unit, Royal Marsden Hospital, Sutton, London, United Kingdom. khurum.khan@icr.ac.uk
PMID